tbuckley/cabot-search huggingface dataset:
THE INSURANCE SPONGE.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE THERAPEUTICAL VALUE OF SUSPENSION IN DISEASES OF THE SPINAL CORD.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Respiratory failure
Authors: C. Roussos, A. Koutsoukou
Journal: European Respiratory Journal (2003)

Respiratory failure occurs due mainly either to lung failure resulting in hypoxaemia or pump failure resulting in alveolar hypoventilation and hypercapnia. Hypercapnic respiratory failure may be the result of mechanical defects, central nervous system depression, imbalance of energy demands and supplies and/or adaptation of central controllers. Hypercapnic respiratory failure may occur either acutely, insidiously or acutely upon chronic carbon dioxide retention. In all these conditions, pathophysiologically, the common denominator is reduced alveolar ventilation for a given carbon dioxide production. Acute hypercapnic respiratory failure is usually caused by defects in the central nervous system, impairment of neuromuscular transmission, mechanical defect of the ribcage and fatigue of the respiratory muscles. The pathophysiological mechanisms responsible for chronic carbon dioxide retention are not yet clear. The most attractive hypothesis for this disorder is the theory of “natural wisdom”. Patients facing a load have two options, either to push hard in order to maintain normal arterial carbon dioxide and oxygen tensions at the cost of eventually becoming fatigued and exhausted or to breathe at a lower minute ventilation, avoiding dyspnoea, fatigue and exhaustion but at the expense of reduced alveolar ventilation. Based on most recent work, the favoured hypothesis is that a threshold inspiratory load may exist, which, when exceeded, results in injury to the muscles and, consequently, an adaptive response is elicited to prevent and/or reduce this damage. This consists of cytokine production, which, in turn, modulates the respiratory controllers, either directly through the blood or probably the small afferents or <i>via</i> the hypothalamic-pituitary-adrenal axis. Modulation of the pattern of breathing, however, ultimately results in alveolar hypoventilation and carbon dioxide retention.
Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial
Authors: S. Badarinath, E. P. Mitchell, A. Jennis, C. D. Graham, V. L. Hansen, C. A. Henderson, T. T. Chen, C. Langer
Journal: Journal of Clinical Oncology (2004)

3531 Background: The EXPLORE study is a randomized phase III study comparing cetuximab (Erbitux) plus FOLFOX4 (5-FU, leucovorin, oxaliplatin), to FOLFOX4 in 2nd-line metastatic, EGFR-positive colorectal cancer (CRC) patients (pts). Since this study is the first experience combining cetuximab with FOLFOX4, an early safety assessment was performed. Methods: The first stage of this randomized phase III trial restricted accrual to 40 pts at 10 centers to obtain an early assessment of safety. Pts with metastatic EGFR-positive CRC who had progressed on prior first-line irinotecan therapy with an ECOG performance status <2 were randomized to either Arm A (cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 weekly dose and FOLFOX4 d1,d2 q 2 weeks) or to Arm B (FOLFOX4 q 2 weeks). A pooled analysis of safety is presented. Results: Forty patients were randomized from March to November, 2003. They included 20 women and 20 men with a mean age of 61 years. Two patients did not receive study therapy and are excluded from the analysis. A total of 178 cycles were administered to the 38 pts with a median of 3 cycles per pt (range 1–15). There have been 4 disease-related deaths and one severe non-fatal hypersensitivity reaction (HSR). A summary table of adverse events associated with chemotherapy and cetuximab is below. The incidence and severity of these events appear comparable to previous reports of cetuximab with chemotherapy or of FOLFOX4. Conclusions: In this pooled analysis the characteristic toxicities of cetuximab and FOLFOX4 do not appear to be increased. The study is continuing to accrue to its target of 1100 patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Roche Bristol-Myers Squibb
The exposure of health care workers to ribavirin aerosol
Authors: Michael J. Harkness
Journal: JAMA (1989)

<h3>To the Editor.—</h3> As a practicing general pediatrician in a community hospital, I have used aerosolized ribavirin frequently for the treatment of lower respiratory distress in infants infected with respiratory syncytial virus.<sup>1</sup>I therefore wish to comment on the letter by Guglielmo et al.<sup>1</sup> During the last few months, several hospitals in our area, including my own, have faced the same dilemma as Guglielmo and colleagues. There seems to be increasing pressure from hospital personnel to delineate further the risk of ribavirin exposure in the workplace, especially to women in their childbearing years. I do not believe the concerns expressed are a result of newly reported cases of teratogenic effects in humans, as I am aware of no case reports of teratogenic, embryolethal, or mutagenic effects in any primate species. I must assume that the new concerns center around the reports of Harrison et al<sup>2</sup>in the
Drug addiction among physicians. The Virginia experience
Authors: R. C. Green
Journal: JAMA (1976)

Drug addiction among physicians appears to be an occupational hazard, with chronic pain, depression, and the easy availability of drugs major factors leading to addiction. In this study of 46 cases of physician addicts handled by the Virginia State Board of Medicine, meperidine hydrochloride (Demerol) was the most frequent addictive agent. The Virginia disciplinary and therapeutic plan for addicted physicians was effective in successfully rehabilitating and returning to medical practice 72% of the 46 physician addicts reported to the board from 1949 to 1974. (<i>JAMA</i>236:1372-1375, 1976)
Therapie innerer Krankheiten.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Barriers to patients’ understanding of prognosis in advanced cancer.
Authors: Jason Palopoli, Tiffany Pompa, Mark Maddox, Adonas Woodard, Sanaa Rizk, Kristine Ward, Pamela A. Crilley, Dave Topolsky, Sigmund Benham Khan, Maneesh Rajiv Jain, Michael Styler
Journal: Journal of Clinical Oncology (2016)

e18155 Background: An informed decision requires good communication between the patient and their oncologist in regards to diagnosis and prognosis, especially in patients with terminal cancer. This discussion entails education about their disease, treatment options, and potential outcomes. The purpose of this study was to assess advanced-stage cancer oncology patients’ comprehension of their disease, treatment options and goals of therapy. Methods: Eligible subjects included patients with a diagnosis of metastatic cancer with an option for palliative or life extending chemotherapy seen in an out-patient setting at Drexel University College of Medicine between 2012-2015. All subjects consented to participate. Participation included completing a 34-item questionnaire about comprehension of their cancer, satisfaction and perception of their physician interaction regarding disease education, and potential barriers to patient understanding. Results: Among the 52 patients analyzed: · 1 patient was not aware he had cancer. · 3 patients (5.7%) thought there was no longer cancer in their bodies. · 33 patients (62%) thought the goal of their therapy was to cure their cancer. · 27 patients (51%) thought the goal of therapy was to extend their life. · 11 patients (20.7%) thought the goal of their therapy was to palliate symptoms. · 5 patients (9.4%) did not know why they were on therapy for their cancer. · 5 patients (9.4%) indicated they had talked about hospice with their doctor. · 5 patients (9.4%) felt they shouldn’t ask any questions. · 48 patients (90.5%) felt they were participating in their treatment decisions. · 4 patients (7.5%) stated they didn’t understand the medical terms used by the doctors. · Compared to what patients wish they knew, almost 30% felt they knew half or very little about their diagnosis and 33% felt they knew half, very little, or nothing about their prognosis. Conclusions: Due to discrepancies between patient understanding and the intended goals of care, our study highlights the need for further guidance in effectively communicating extent of disease and predicted outcome. It is also important to periodically ask patients to discuss their understanding of their diagnosis, prognosis, and treatment options.
Methadone maintenance treatment. A ten-year perspective
Authors: V. P. Dole
Journal: JAMA (1976)

TEN YEARS ago inThe Journal, we reported on the use of methadone hydrochloride to treat a small group of intractable heroin addicts. The encouraging results of this pilot experiment suggested that larger-scale maintenance programs might provide a treatment alternative for a significant number of heroin addicts. To some extent this expectation has been supported by the experience of clinicians using methadone in treatment programs throughout the United States and abroad. Many thousands of former heroin addicts have been rehabilitated, but on balance today, it must be recognized that the projections of ten years ago were overly optimistic. The great majority of heroin addicts in our cities remain on the streets, and the programs have lost their ability to attract them to treatment. An unfortunate consequence of the early enthusiasm for methadone treatment is today's general disenchantment with chemotherapy for addicts. What was not anticipated at the onset was the
Addendum
Journal: BMJ (1869)

THE BRITIS 1 MEDICAL _OURNAL.[Oct.i6, I869.various stand-points, and in the interpretation of her language by dif- ferent minds, that our store of knowledge is extended; and he who works in an honest spirit, even though he fail to read her lessons aright, may still have donie some service in helping forward the cause of Truth. ADDENDUM.THIS woodcut, from a drawing by Dr. Stewart, the Curator of the Museum at St. Tlhomolas's Hospital, exemplifies the condition alluded to n a former Lectturc, in which tlhe pri-imitiVe miiusctular fibires arc found ecchymose(l, disiniteg-rated, and ruptured, in tetanus.The specimen was taken from the patienut referred to in the text, who died of acute traumatic tetanus; aind is magnified 300 diameters.
Stunned vs hibernating myocardium
Authors: C. J. Gbur
Journal: JAMA (1990)

<h3>In Reply.—</h3> Drs Senecal and Osterloh raise concerns regarding the clinical correlation and the diagnosis of bromide intoxication in our patient. However, we still consider this diagnosis valid. As pointed out in our article, we also believe that this level of bromide is what would be considered by most to be below a toxic level. Although symptoms are not "usually" seen at this level, we believe that the temporal relationship of symptoms, as well as the peak negative anion gap, correlates with the high dose of pyridostigmine bromide and the bromide level measured. The normal half-life of bromide may have been easily reduced with the use of intravenous crystalloid solution, as was noted in our report, and this may have contributed to the rapid resolution of symptoms. Drs Senecal and Osterloh also question whether an oral dose of 1 mg of levorphanol tartrate could have influenced the encephalopathic picture in
JAMA reference directories
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Computed tomographic examination of heavy marijuana smokers
Authors: J. Kuehnle
Journal: JAMA (1977)

Computed tomographic scans were obtained from 19 men with long histories of heavy marijuana smoking and who were also observed to smoke large amounts of marijuana under research ward conditions. The ventricular system and subarachnoid spaces were normal in size and showed no indication of atrophic change. (<i>JAMA</i>237:1231-1232, 1977)
Neurodevelopment After In Utero Exposure to Phenytoin and Carbamazepine-Reply
Authors: Gideon Koren
Journal: JAMA (1994)

<h3>In Reply.</h3> —Careful reading of our study would have revealed to Dr Jeret that separate analysis of only the epileptic cases did not result in an outcome different from those treated with carbamazepine for nonepileptic indications (top of page 769). Careful reading would have revealed to him also that there was no correlation between the daily dose per kilogram of either phenytoin or carbamazepine and global IQ (page 769). Last, careful reading would have disclosed that this study did not compare the two AEDs with each other, but rather with tightly matched controls. That "full dose" phenytoin is associated with serious neurotoxicity to fetuses is certainly concerning and should be communicated to mothers to be. Drs Loring, Meador, and Thompson believe that we should have conducted a different analysis than we have done. The essence of their complaint is that we should have compared the phenytoin and carbamazepine cohorts with
Microalbuminuria, Lipoproteins, and Diabetic Control
Authors: Luis C. Ramirez
Journal: Annals of Internal Medicine (1993)

Letters15 February 1993Microalbuminuria, Lipoproteins, and Diabetic ControlLuis C. Ramirez, MD and Philip Raskin, MDLuis C. Ramirez, MDSearch for more papers by this author and Philip Raskin, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-4-199302150-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Drs. Bostom, Wilson, and Manske correctly point out the need to determine whether the association of poor diabetic control and high Lp(a) levels persists after controlling for an elevated urinary albumin excretion rate. Unfortunately, we did not measure urinary albumin excretion rates.Lipoprotein(a) has a high degree of homology with plasminogen, a key protein of the fibrinolytic system [1]. It has been postulated that Lp(a) may compete with plasminogen at the level of the binding site and prevent fibrinolysis, thus promoting a procoagulant state [2]. We found no correlation, however, between Lp(a) levels and fibrinolysis in a group ...References1. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, et al. Partial amino acid sequences of apolipoprotein (a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA. 1987; 84. Google Scholar2. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature. 1989; 339:301-3. Google Scholar3. Arauz-Pacheco C, Ramirez LC, Pruneda L, Allison P. Relationship between fibrinolysis and lipoprotein (a) (Lp [a]), plasma lipids and glucose control in diabetes. Diabetes. 1992; 41(Suppl 1):112A. Google Scholar4. Ramirez L, Rosenstock J, Arauz C, Hellenbrand D, Raskin P. Low prevalence of microalbuminuria in normotensive patients with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1991; 12:85-90. Google Scholar5. Jensen T, Stender S, Deckert T. Abnormalities in plasma concentrations of lipoprotein and fibrinogen in type I (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia. 1988; 31:141-5. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 February 1993Volume 118, Issue 4Page: 312-313KeywordsAlbuminsDiabetes mellitusExcretionFibrinolysisInsulinLipoproteinsMicroalbuminuriaProspective studiesProteinsStable coronary artery disease Issue Published: 15 February 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
The Dalkon Shield controversy. Structural and bacteriological studies of IUD tails
Authors: H. J. Tatum
Journal: JAMA (1975)

The recent report of 209 cases of septic spontaneous abortion and 11 maternal deaths in the United States in women using the Dalkon Shield intrauterine device (IUD) raised the question about a possible causal relationship between the IUD and pelvic sepsis. It is essential to determine whether or not this sepsis is unique to the Dalkon Shield or generic to all types of IUDs. Our studies permit the conclusion that the tail of the Dalkon Shield is structurally and functionally different from the tails of the four other IUDs tested. The unique characteristics of the Dalkon tail theoretically could provide a mechanism whereby pathogenic bacteria from the vagina enter the uterine cavity and cause sepsis. (<i>JAMA</i>231:711-717, 1975)
P-312 A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab in Patients with KRAS Wild Type Metastatic Colorectal Cancer
Authors: R. Huhn, J. Lowe, M. Grady, C. Taitt, A. Braun
Journal: Annals of Oncology (2015)
Comprehensive Assessment of the Elderly Cancer Patient: The Feasibility of Self-Report Methodology
Authors: Sally S. Ingram, Pearl H. Seo, Robert E. Martell, Elizabeth C. Clipp, Martha E. Doyle, Gustavo S. Montana, Harvey J. Cohen
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Comprehensive geriatric assessment (CGA) has aided the medical community greatly in understanding the quality-of-life issues and functional needs of older patients. With its professional team assessment approach, however, CGA may be time consuming and costly. The goal of the present study was to assess the ability of cancer patients to complete a self-administered CGA and then to characterize cancer patients across multiple domains and age groups. PATIENTS AND METHODS: Two hundred sixty-six male outpatient oncology patients at the Durham Veterans Affairs Medical Center were asked to fill out a survey assessing 10 domains (demographics, comorbid conditions, activities of daily living, functional status, pain, financial well being, social support, emotional state, spiritual well-being, and quality of life). RESULTS: Seventy-six percent of the patients who received their surveys and kept their appointments returned the assessment tool. Older oncology patients had significantly less education (P &lt; .0001), income (P = .05), frequent exercise (P = .01), and chance of being disease free (P = .003) than younger patients. Other findings in older patients were a higher rate of marriage (P = .02), more difficulty in taking medications (P = .05), and less cigarette (P = .03) and alcohol (P = .03) use. Members of all age cohorts reported a sense of social support, with younger patients deriving this more from family and friends than older patients, and older patients deriving social support more from membership in religious communities than younger patients. No differences were found across age groups for number and impact of comorbid illnesses, number of medications, basic and instrumental activities of daily living, pain, overall health rating, financial adequacy, anxiety, depression, and quality of life. CONCLUSION: CGA can be conducted in an outpatient cancer community using a self-report format. Despite the fact that this population varied demographically across age groups and is limited to veterans, this study demonstrated remarkable similarities between younger and older cancer patients in terms of functional status, health states, and quality of life.